-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

626.O1.6 626. Aggressive Lymphomas Prospective Therapeutic Trials: Novel Agents and Combinations Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Lymphomas, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Diseases, Therapies, aggressive lymphoma, Lymphoid Malignancies
Sunday, December 12, 2021: 4:30 PM-6:00 PM
Thomas Murphy Ballroom 1-2, Level 5, Building B (Georgia World Congress Center)
Moderators:
Mark Roschewski, MD, National Cancer Institute and Laurie H. Sehn, MD, British Columbia Cancer Agency
Disclosures:
Sehn: Novartis: Consultancy; Genmab: Consultancy; Debiopharm: Consultancy; Teva: Consultancy, Research Funding; Roche/Genentech: Consultancy, Research Funding; AbbVie: Consultancy; Acerta: Consultancy; Amgen: Consultancy; Apobiologix: Consultancy; AstraZeneca: Consultancy; Celgene: Consultancy; Gilead: Consultancy; Incyte: Consultancy; Janssen: Consultancy; Kite: Consultancy; Karyopharm: Consultancy; Lundbeck: Consultancy; Merck: Consultancy; Morphosys: Consultancy; Sandoz: Consultancy; Seattle Genetics: Consultancy; Takeda: Consultancy; TG Therapeutics: Consultancy; Verastem: Consultancy.
4:30 PM

Jeremy S. Abramson, MD1, Amy S. Ruppert, PhD2,3, Sharmila Giri, MS2,4*, Ann Hudson2,4*, Eric D. Hsi, MD5, Richard F. Little, MD, MPH6, Steven D. Gore, MD6, Anusha Vallurupalli, MD7*, Daniel J Landsburg, MD8, Brad S. Kahl, MD9, Jonathan W. Friedberg, MD10, Nancy L. Bartlett, MD9 and John P. Leonard, MD11

1Massachusetts General Hospital Cancer Center, Boston, MA
2Alliance Statistics and Data Center, Rochester, MN
3Center for Biostatistics, The Ohio State University, Columbus, OH
4Mayo Clinic, Rochester, MN
5Department of Pathology, Wake Forest Baptist Medical Center, Winston Salem, NC
6Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD
7University of Kansas Cancer Center, Kansas City, KS
8Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
9Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
10Wilmot Cancer Institute, University of Rochester, Rochester, NY
11Weill Cornell Medicine, New York, NY

4:45 PM

Mark Roschewski, MD1, James D. Phelan, PhD2*, Stefania Pittaluga, MD, PhD3, Christopher Melani, MD4, Rahul Lakhotia, MBBS2, Jacob J. Chabon, PhD5*, Jagan R. Muppidi, MD, PhD2*, Kathryn A. Lurain, MD, MPH6,7, Jillian Simard, MD2, Amynah Pradhan, CRNP-F2*, Amy Hillsman, CRNP2*, Madeline Rilko, RN2*, Seth M. Steinberg, PhD8*, George W. Wright, PhD9*, Da Wei Huang, MD2*, Yandan Yang, PhD9*, Michail S. Lionakis, MD, ScD10*, Alexander Bagaev, PhD11*, Ekaterina Postovalova, PhD11*, Mark Meerson, MS12*, Olga Kudryashova, MS12*, Nikita Kotlov, MS12*, Nathan H. Fowler, MD12, David M. Kurtz, MD, PhD13, Ash A. Alizadeh, MD, PhD14, Elaine S. Jaffe, MD3, Louis M. Staudt, MD, PhD2 and Wyndham H. Wilson, MD, PhD2

1Lymphoid Malignancies Branch, Center for Cancer Research, Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, MD
2Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
4Lymphoid Malignancies Branch, Center for Cancer Research, National Institutes of Health, Derwood, MD
5Foresight Diagnostics, Aurora, CO
6HIV/AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD
7National Cancer Institute, Bethesda, MD, USA, Bethesda, MD
8Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD
9Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda
10Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
11BostonGene Corp., Waltham, MA
12BostonGene, Corp, Waltham, MA
13Stanford University, Stanford, CA
14Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA

5:00 PM

Martin Hutchings1*, Anna Sureda2, María José Terol, MD PhD3*, Francesc Bosch Albareda4*, Paolo Corradini, MD5, Thomas Stauffer Larsen6*, Antonio Rueda Dominguez7*, Anesh Panchal8*, Alessia Bottos9*, David Carlile8*, Yanjie Wang10*, Audrey Filézac De L'Étang9*, Maneesh Tandon8*, Gila Sellam9* and Giuseppe Gritti11*

1Rigshospitalet, Copenhagen, Denmark
2Universitat de Barcelona, Barcelona, Spain
3Hospital Clínico Universitario INCLIVA, University of Valencia, Valencia, Spain
4University Hospital Vall d'Hebron, Barcelona, Spain
5University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
6Odense University Hospital, Odense, Denmark
7Regional and Virgen de la Victoria University Hospitals, Málaga, Spain
8Roche Products Ltd, Welwyn Garden City, United Kingdom
9F. Hoffmann-La Roche Ltd, Basel, Switzerland
10F. Hoffmann-La Roche Ltd, Shanghai, China
11Ospedale Papa Giovanni XXIII, Bergamo, Italy

5:15 PM

Moshe Y. Levy, MD1, Deepa Jagadeesh, MD2, Zhanet Grudeva-Popova, MD3*, Marek Trněný, MD4, Wojciech Jurczak, MD, PhD5*, Halyna Pylypenko6*, Marc André, MD7*, Sunita Dwivedy Nasta, MD8, Dalit Rechavi-Robinson9*, Sara Toffanin9*, Sandrine Micallef9*, Antoine Attinger9*, Elisabeth Rouits9*, Marie-Claude Roubaudi-Fraschini9*, Panos Orfanos9*, Mariola Dymkowska, MD9*, Heidi Nauwelaerts9* and Sherida Woei-a-Jin, MD MSc10*

1Baylor Charles A. Sammons Cancer Center, Dallas, TX
2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, BGR
4First Dept. of Medicine- Hematology, Charles University General Hospital and First Faculty of Medicine, Prague, Czech Republic
5Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
6Regional Treatment and Diagnostics Haematology Centre, Cherkassy Regional Council, Cherkassy, Ukraine
7Department of Hematology, CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium, Yvoir, Belgium
8Lymphoma Program, University of Pennsylvania Medical Center, Philadelphia, PA
9Debiopharm International SA, Lausanne, Switzerland
10Department of Hematology, University Hospitals Leuven, Leuven, Belgium

5:30 PM

John M. Burke, MD1, Gustavo Fonseca, MD2*, Wojciech Jurczak, MD, PhD3*, Jason Melear, MD4, Miguel Islas-Ohlmayer, MD5, James A Reeves, MD6*, Parameswaran Venugopal, MD7, Tomasz Wróbel, MD, PhD8, Don Stevens, MD9, John M. Pagel, MD, PhD10, Jerome Goldschmidt, MD11*, Hari P. Miskin, MSc12, Peter Sportelli, BS12, Owen A. O'Connor, MD, PhD12* and Nilanjan Ghosh, MD, PhD13

1Rocky Mountain Cancer Centers / US Oncology Research, Aurora, CO
2Florida Cancer Specialists North/Sarah Cannon Research Institute, St. Petersburg, FL
3Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
4Texas Oncology, Austin, TX
5Oncology Hematology Care, Cincinnati, OH
6Florida Cancer Specialists South / Sarah Cannon Research Institute, Fort Myers, FL
7Rush University Medical Center, Chicago, IL
8Department of Hematology, Wroclaw Medical University, Wroclaw, Poland
9Norton Cancer Institute, Louisville, KY
10Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
11Blue Ridge Cancer Care / US Oncology Research, Blacksburg, VA
12TG Therapeutics, Inc., New York, NY
13Department of Hematology, Lymphoma Division, Assistant Professor of Medicine, Levine Cancer Institute/Atrium Health, Charlotte, NC

5:45 PM

Michael Wang, MD1, Matthew Mei, MD2, Paul M. Barr, MD3, Jacqueline Barrientos, MD, MS4, Sven de Vos5, Richard Furman6, Krish Patel7*, Philip A. Thompson1, Michael Choi8, Avyakta Kallam, MD9, Ying Zhu10*, Samhita Chakraborty10*, Patricia Marinello10* and Stephen E. Spurgeon11

1MD Anderson Cancer Center, Houston, TX
2City of Hope Cancer Center, Duarte, CA
3University of Rochester, Rochester, NY
4Northwell Health, Inc., New Hyde Park, NY
5UCLA Santa Monica Medical Center, Santa Monica, CA
6Weill Cornell Medical College, New York, NY
7Swedish Cancer Institute, Seattle, WA
8University of California San Diego, San Diego, CA
9University of Nebraska Medical Center, Omaha, NE
10Merck & Co., Inc., Kenilworth, NJ
11Oregon Health and Science University, Portland, OR

*signifies non-member of ASH